Supplementary Figure 2: Effect of mutations of the C-terminal extension of
Mtb-HigA1 on the suppression of Mtb-HigB1 toxicity (related to Fig. 1 ). a, Steady state expression level of Mtb-HigB1 toxin is not affected by mutations in Mtb-HigA1 antitoxin in E. coli. Double transformants of strainW3110 secB were grown to midlog phase and expression of both MtbhigBA1 and Mtb-SecB TA was induced for 1h with 0,1% arabinose and 50µM IPTG, respectively. Whole-cell extracts were separated by SDS-PAGE and analyzed by western blot using anti-MtbHigB1 antibodies. Full blots for (a) are shown in Supplementary Fig. 6 . b, Strain W3110 ΔsecB containing the plasmid pSE-vector (-) or pSE-Mtb-SecB TA was transformed with pK6-MtbHigBA1 wild type, ΔC42 or W108A/W137A. Double transformants were grown in LBampicillin-kanamycin to midlog phase, serially diluted, and spotted on LB-ampicillin-kanamycin agar plates with arabinose and IPTG as indicated. Plates were incubated at 37°C overnight. c, Strain W3110 ΔsecB containing the plasmid pSE-vector (-) or pSE-Mtb-SecB TA was transformed with pK6-Mtb-HigBA1 wild type, or with the single W108A or W137A mutants. Double transformants were grown in LB-ampicillin-kanamycin to midlog phase, serially diluted, and spotted on LB-ampicillin-kanamycin agar plates with arabinose and IPTG as indicated. Plates were incubated at 37°C overnight. Fig. 1 and 3) . Plasmid pLAM12 derivatives co-expressing the toxin MtbHigB1 and the antitoxin Mtb-HigA1 either wild type or carrying the ΔC42, W108A/W137A, WHR(108-110)AAA or Y114A mutations under the control of an acetamide inducible promoter were electroporated into the M. smegmatis MC 2 155 pGMC-Rv1957 strain, which has the MtbSecB TA chaperone integrated at the L5 phage attachment site under the control of an anhydrotetracycline inducible promoter. After 4 hours of incubation at 37°C, 1/100 of the transformations were directly plated on LB agar plates containing Streptomycin (25µg/mL) and Kanamycin (5µg/mL) with and without 20ng/mL anhydrotetracycline (ATc) to induce or not the expression of the chaperone. Plates were incubated at 37°C for 48h. lovleyi are bona fide TAC in E. coli. Strain W3110 secB was co-transformed with pSE vector (-) or pSE-Mmet-SecB TA and pK6-Mmet-HicAB (left), or pSE-Vcho-SecB TA and pK6-Vcho-MqsRA (center), or pSE-Glov-SecB TA and pK6-Glov-HigBA (right), on LB-ampicillin-kanamycin agar plates containing 0.2% glucose at 37°C. Double transformants were grown in LB-ampicillinkanamycin to midlog phase, serially diluted, and spotted on LB-ampicillin-kanamycin agar plates with IPTG and arabinose inducers as indicated. Plates were incubated at 37°C overnight. c, Schematic representation of M. methanica (left), V. cholerae (center) and G. lovleyi (right) antitoxins. The TAC specific C-terminal extensions (hachures) and their amino acid sequences are shown. d, M. methanica, V. cholerae, G. lovleyi SecB-like chaperones replace SecB in E. coli. Transformants of W3110 ΔsecB containing pSE derivatives harboring SecB-like chaperones were spotted on LB-ampicillin with or without IPTG, and incubated at the indicated temperature. e, Expression of SecB TA chaperones. Transformants of W3110 ΔsecB containing pSE-SecB-like chaperone derivatives were grown to midlog phase, IPTG (50mM) was added for 2 hours. Wholecell extracts were separated by SDS-PAGE and stained with Coomassie. (a, b, c, d) are the same as in Fig. 1b . In vivo pulldowns of His-tagged Mtb-SecB TA and the pK6-Luc constructs and whole cell extracts were revealed with anti-Luciferase (e) or anti-Mtb-SecB TA (f) antibodies. Blots in (e, f) are the same as in Fig. 1c . In vivo pulldown of His-tagged MtbSecB TA and Mtb-HigA1 (wild type) or Mtb-HigA1 Y114A (Y114) proteins, and whole cell extracts were revealed using anti-Mtb-HigA1 (g and h) or anti-Mtb-SecB TA antibodies (i and j). Blots in (g, h, i, j) are the same as in Fig. 3e . Mtb-HigB1 steady state expression levels in the presence of Mtb-HigA1 (k), Mtb-HigA1 W108A/W137A (l) or Mtb-HigA1 ΔC42 (m). Blots in (k, l, m) are the same as in Supplementary Fig. 2a . 
